Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women

Journal of Acquired Immune Deficiency Syndromes

Volumn 37, Issue 5, 2004, Pages 1577-1580

  Min, Sherene S ^a   Corbett, Amanda H ^b   Rezk, Naser ^b   Cu Uvin, Susan ^c   Fiscus, Susan A ^a   Petch, Leslie ^b   Cohen, Myron S ^a   Kashuba, Angela D M ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

Antiretroviral concentration; Female genital tract; HIV 1; Nonnucleoside reverse transcriptase inhibitor; Pharmacokinetic; Protease inhibitor

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; EFAVIRENZ; INDINAVIR; LOPINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; FEMALE GENITAL SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; BODY FLUIDS; CERVIX UTERI; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; VAGINA;

EID: 10644295700     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200412150-00008     Document Type: Article

References (13)

1. Joint United Nations Programme on HIV/AIDS and World Health Organization AIDS epidemic update: December 2003. www.unaids.org. Accessed March 2004.
2. Sutthent R, Sumrangsurp K, Wirachsilp P, et al. Diversity of HIV-1 subtype E in semen and cervicovaginal secretion. J Virol. 2001;4:260-268.
3. Panther LA, Tucker L, Xu C, et al. Genital tract human immunodeficiency virus type 1 (HIV-1) shedding and inflammation and HIV-1 env diversity in perinatal HIV-1 transmission. J Infect Dis. 2000;181:555-563.
4. Overbaugh J, Anderon RJ, Ndinya-Achola JO, et al. Distinct but related human immunodeficiency virus type 1 variant populations in genital secretions and blood. AIDS Res Hum Retroviruses. 1996;12:107-115.
5. Yerly S, Kaiser I, Race E, et al. Transmission of antiretroviral-drug- resistant HIV-1 variants. Lancet. 1999;354:729-733.
6. Si-Mohamed A, Kazatchkine M, Heard I, et al. Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type-1-infected women receiving antiretroviral therapy. J Infect Dis. 2000;182:112-122.
7. Reichelderfer PS, Coombs RW, Wright DJ, et al. Effect of menstrual cycle on HIV-1 levels in the peripheral blood and genital tract. AIDS. 2000; 14:2101-2107.
8. Rezk NL, Tidwell RR, Kashuba ADM. Simple and rapid quantification of the non-nucleoside reverse transcriptase inhibitors nevirapine, delavirdine, and efavirenz, in human blood plasma using high-performance liquid chromatography with ultraviolet absorbance detection. J Chromatograph B. 2002;774:79-88.
9. Usala SJ, Schumacher GFB. Volumetric self-sampling of cervicovaginal fluid: a new approach to ovulation timing. Fertil Steril. 1983;39:304-309.
10. Kashuba ADM, Dyer JR, Kramer LM, et al. Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1999; 43:1817-1826.
11. Vernazza PL, Kashuba ADM, Cohen MS. Biological correlates of sexual transmission of HIV: practical consequences and potential targets for public health. Rev Med Microbiol. 2001;12:131-142.
12. Fleishaker JC. Models and methods for predicting drug transfer into human milk. Adv Drug Deliv Rev. 2003;55:643-652.
13. Herrera IG, Pearson RM, Turner P. Quantitation of albumin and alpha-1-acid glycoprotein in human cervical mucus. Hum Exp Toxicol. 1991;10:37-139.